Evaluating early cholinergic degeneration in preclinical Alzheimer’s disease using F18 fluoroethoxybenzovesamicol ([18F] FEOBV) and F18 Florbetaben ([18F]FBB)) PET Imaging “The Sterling's Dream Study”

Occurring Dates
to
Participant Duration
Duration of participant involvement: 2 assessments totalling 4-5 hours; 2 imaging days.
State of study
Queensland
Overview

The study is investigating the use of innovative methods of clinical assessment and imaging to better understand Alzheimer’s disease. Clinical and imaging tests target the loss of cholinergic function known to be associated with Alzheimer’s disease but not previously specifically tested. The study team is employing a multi-dimensional suite of cognitive tests, including computerised navigational tasks, in conjunction with PET scans, which will measure basal forebrain cholinergic function and amyloid accumulation in people with and without early stage Alzheimer’s disease. It is anticipated these innovative techniques will facilitate diagnosis and earlier targeted therapies.

We are inviting people with and without Alzheimer’s disease to participate in the study.

Further information

For further information or to participate, please contact Anne Bucetti on (07) 3139 7208 or at [email protected].

The ethical aspects of this study have been approved by The Prince Charles Hospital Human Research Ethics Committee (HREC/15/QPCH/7).
This study is led by Dr Eamonn Eeles and has received funding from The Common Good, The Prince Charles Hospital Foundation.

Study Address
The Prince Charles Hospital
Rode Road, Chermside
Brisbane QLD 4032
Full Name
Anne Bucetti
Institute
The Prince Charles Hospital
Phone Number
(07) 3139 7208